A Family office based in the United States focuses on investments in the healthcare industry. The firm’s investment size can vary greatly and is very flexible depending on each company’s needs. The firm provides venture growth capital to healthcare companies and typically invests in equity or convertible preferred equity after the series A round. For growth investments, the firm targets companies with compelling products and strong position in niche markets and with an EBITDA in excess of $2 million. The firm primarily invests in companies based in US.

The firm will consider investments in Medical Devices, Diagnostics and Healthcare IT sectors. For early-stage investments, the firm targets companies that provide solutions for hospital acquired infections, medication errors, patient monitoring, healthcare system operational efficiency enhancements and cost reductions, and chronic disease management. The firm does not invest in companies developing small molecule or devices that need PMA. For medical device sector, the firm is most interested in class I and class II devices. The firm will not consider companies in pre-clinical stage, and typically invests in companies that are near or have reached commercialization.

The firm focuses on private companies with strong and experienced management team. The firm usually takes a board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US based venture capital fund is looking to make seed and series A stage investments into life science companies with investments ranging anywhere from $500,000 initially to $25 million over the lifetime of the investment. The firm is actively reviewing opportunities throughout the United States and could make as many as 6 investments over the next year.

Within the life science space the firm is primarily focused on therapeutics. Within therapeutics the firm is opportunistic in terms of technology type and is open to both single asset and platform technology companies. The firm is most interest in companies targeting white space indications and is generally less interest in highly crowded areas including diabetes, Alzheimer’s and solid tumors. The firm is primarily interest in pre-clinical companies however they are open to later stage technologies as well pending it is a series A round or earlier.

The firm is looking for companies with experienced management teams and is very open to working with incomplete management teams. The firm looks to act as an active value adding investor and requires a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm that that is based China with additional offices in Asia and the US currently manages over $750 million in committed capital across 7 funds. The most recent fund closed at $110 million in 2011 focuses on making equity investments into early-stage companies in Technology, Clean Technology and Healthcare sectors. The typical investment size ranges from $5 million to $15 million. The firm primarily looks to invest in companies based in China and US.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices, Healthcare IT and Advanced Materials sectors. The firm is very opportunistic in terms of subsectors and indications, and is open to all classes of devices. The firm prefers to invest companies in pre-clinical and clinical stage, but it is open to consider companies with products on the market. Historically, the firm was active in companies developing diagnostic services and instrumentation, fetal monitoring and ultrasound systems, and vascular closure devices.

The firm invests in both private and public companies with a strong management team. The firm doesn’t have specific requirements for companies’ revenue or EBITDA. The firm looks to take a Board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Global High-tech companies makes equity investments and is seeking strategic partnerships with early-stage companies. The firm’s equity investments are typically of $1-3 million although the firm is very capable of making allocation outside this range as well.

Within the life science space the firm focuses on the backend of connected healthcare, with the goal of using communications technology to enable a network of care, with the patient at the center using devices to share information with healthcare professionals and with family members and other careers. The firm is therefore investing primarily in medical devices and lab equipment that transmit information wirelessly, particularly those that bring innovation to hospitals and clinics. The firm generally does not invest in equipment used in very complex wet chemistry (such as assay equipment) but is otherwise open to considering any innovations involving transmitting data from devices in the healthcare and biotech R&D equipment field. The firm is also open to healthcare IT opportunities. In addition to wireless data transmission, the firm’s technological focus in the healthcare field includes very small vital sensors and variable power technologies that can deliver increased battery life. The firm prefers to invest in technologies that are at commercialization stage or close to approval, but earlier stage opportunities may be of interest. While the firm will consider any indication, elder care is of particular interest, and the firm also has programs in the consumer health, wellness and beauty fields.

The firm only invests in companies that are interested in a long-term strategic partnership with the firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a global science-based company active in health, nutrition and materials is looking The firm makes equity investments into seed and venture stage companies. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Israel.

The firm is looking for companies in the intersection of Life and Materials Sciences. These includes companies developing devices and materials targeting indications of cardiovascular, orthopedics, ophthalmology, dental, drug delivery and next generation cellular therapy. The firm is also interested in companies in the Agbio and nutraceutical spaces. While the firm has invested in companies all the way from seed to 3-month pre-IPO, they generally invest into companies that do not yet have a product on the market.

The firm highly values experience in a firm’s management team and generally looks to take a board seeks and play an active role in its portfolio companies. The firm is looking for companies that are in cooperation/alignment with the parent business.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of subsidiary of a US healthcare provider has closed its third fund at $225 million in 2012.The firm makes equity investments into early-stage companies of approximately $3 million to $10 million initially with additional capital reserved for follow on financings, and generally it can invest $4 million to $15 million over a life cycle. The firm seeks to invest in companies in Series A & B financing rounds, but it is open to consider companies in other stages of development. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US.

The firm is currently looking for new opportunities in the Medical Devices, Diagnostics, Healthcare IT and Healthcare Services spaces. The firm considers all classes of medical devices and focuses on companies in the clinical stage. However, the firm will also considers products that are on the market. The firm is generally opportunistic in terms of indication.

The firm primarily invests in pre-revenue private companies. The firm looks to invest in companies with a strong management team who can demonstrate relevant experience, depth and capability to build and scale the business and attract customers Ascension Ventures typically requests a Board seat or Board observation rights for each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a global science-based company active in health, nutrition and materials is looking The firm makes equity investments into seed and venture stage companies. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Israel.

The firm is looking for companies in the intersection of Life and Materials Sciences. These includes companies developing devices and materials targeting indications of cardiovascular, orthopedics, ophthalmology, dental, drug delivery and next generation cellular therapy. The firm is also interested in companies in the Agbio and nutraceutical spaces. While the firm has invested in companies all the way from seed to 3-month pre-IPO, they generally invest into companies that do not yet have a product on the market.

The firm highly values experience in a firm’s management team and generally looks to take a board seeks and play an active role in its portfolio companies. The firm is looking for companies that are in cooperation/alignment with the parent business.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com